Engineered immune cells take aim at Hard-to-Treat multiple myeloma
NCT ID NCT03455972
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether giving patients with high-risk multiple myeloma specially engineered T-cells (CAR T-cells) after a stem cell transplant can safely improve outcomes. The T-cells are designed to target two proteins on myeloma cells, CD19 and BCMA. Researchers are monitoring side effects and how long the cancer stays under control in 43 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19 and anti-BCMA CAR T-cells
What this could lead to
If successful, this could offer a more effective way to control high-risk multiple myeloma after a stem cell transplant, potentially extending remission and survival.
What could go wrong
This is an early-phase trial with only 43 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND EFFICACY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital, Soochow University
Suzhou, Jiangsu, 215000, China